Giel-Moloney, M. and Esteban, M. and Oakes, B. H. and Vaine, M. and Asbach, B. and Wagner, R. and Mize, G. J. and Spies, A. G. and McElrath, J. and Perreau, M. and Roger, T. and Ives, A. and Calandra, T. and Weiss, D. and Perdiguero, B. and Kibler, K. V. and Jacobs, B. and Ding, S. and Tomaras, G. D. and Montefiori, D. C. and Ferrari, G. and Yates, N. L. and Roederer, M. and Kao, S. F. and Foulds, K. E. and Mayer, B. T. and Bennett, C. and Gottardo, R. and Parrington, M. and Tartaglia, J. and Phogat, S. and Pantaleo, G. and Kleanthous, H. and Pugachev, K. V. (2019) Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. SCIENTIFIC REPORTS, 9: 20005. ISSN 2045-2322,
Full text not available from this repository. (Request a copy)Abstract
Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effective vaccine against HIV. In this study, an alternative replication-defective flavivirus vector, RepliVax (RV), was evaluated for the delivery of HIV-1 immunogens. Recombinant RV-HIV viruses were engineered to stably express clade C virus Gag and Env (gp120TM) proteins and propagated in Vero helper cells. RV-based vectors enabled efficient expression and correct maturation of Gag and gp120TM proteins, were apathogenic in a sensitive suckling mouse neurovirulence test, and were similar in immunogenicity to recombinant poxvirus NYVAC-HIV vectors in homologous or heterologous prime-boost combinations in mice. In a pilot NHP study, immunogenicity of RV-HIV viruses used as a prime or boost for DNA or NYVAC candidates was compared to a DNA prime/NYVAC boost benchmark scheme when administered together with adjuvanted gp120 protein. Similar neutralizing antibody titers, binding IgG titers measured against a broad panel of Env and Gag antigens, and ADCC responses were observed in the groups throughout the course of the study, and T cell responses were elicited. The entire data demonstrate that RV vectors have the potential as novel HIV-1 vaccine components for use in combination with other promising candidates to develop new effective vaccination strategies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROTECTIVE EFFICACY; GENE-EXPRESSION; ENV CLONES; DNA PRIME; VIRUS; ANTIBODIES; BALANCE; NYVAC; INFECTIONS; CHALLENGES; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Mar 2020 09:29 |
| Last Modified: | 19 Mar 2020 09:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25650 |
Actions (login required)
 |
View Item |
